ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance GlobeNewswire August 07, 2025 SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. […]
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results GlobeNewswire August 07, 2025 Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the Phase 1 trial of LNCB74 (B7-H4 ADC)
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire August 07, 2025 DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to eight
Tyson Foods Announces Quarterly Dividend and Increase in Authorization Under Share Repurchase Program GlobeNewswire August 07, 2025 SPRINGDALE, Ark., Aug. 07, 2025 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN) announced today that its board of directors has declared a quarterly dividend of $0.50 per share on Class A common stock and $0.45 per share
Globalink Investment Inc. Announces Extension of the Deadline to Complete a Business Combination to September 9, 2025 GlobeNewswire August 07, 2025 New York, NY, Aug. 07, 2025 (GLOBE NEWSWIRE) — Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company“), a special purpose acquisition company, announced today that on August 5, 2025,
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire August 07, 2025 Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After
Kura Oncology Reports Second Quarter 2025 Financial Results GlobeNewswire August 07, 2025 – FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with
Inuvo Posts 25% Growth in the Second Quarter 2025 Management to host conference call at 4:15 PM ET, Thursday, August 7, 2025 GlobeNewswire August 07, 2025 LITTLE ROCK, Ark., Aug. 07, 2025 (GLOBE NEWSWIRE) — Inuvo, Inc. (NYSE American: INUV), a leading provider of artificial intelligence AdTech solutions, today announced its financial results for the
Nuvini Launches NuviniAI Lab to Accelerate AI Adoption Across Portfolio Companies and Drive Scalable Growth GlobeNewswire August 07, 2025 NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), Latin America's leading serial acquirer of B2B SaaS companies, today announced the official launch of NuviniAI Lab, a dedicated
Regeneron Announces Investor Conference Presentations GlobeNewswire August 07, 2025 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Cantor Global Healthcare Conference 2025 at 1:35 p.m. ET on Wednesday, September 3, 2025 2025 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, September 4,